Latest news
Start-Up of the Year Award Auvergne-Rhône-Alpes for Jacky Vonderscher and ENYO Pharma
The 26th edition of the Entrepreneur of the year Auvergne-Rhone-Alpes took place on September 17th, 2018 in Lyon. The “Start-Up of the Year” Award has been granted to Jacky Vonderscher, CEO of ENYO Pharma. This Award recognizes the company both for its high innovation on the biotech market and its high growth leading ENYO Pharma to become one of the leaders of tomorrow. Thus, the company reached the next step of the “Entrepreneur of the year” Award which will take place at national level on October 18th 2018 in Paris!
EIC Innovator’s Summit 2018
ENYO Pharma was present at the EIC Innovators’ Summit in Berlin on September, 10th-11th 2018, organized by the European Innovation Council. We had the pleasure to make presentations at several workshops during this summit. The workshops allowed participants to be creative and to strengthen their knowledge thanks to several experience sharings of our team members. On this occasion, it was a great opportunity for ENYO Pharma to have fruitful meetings and conversations,
Posters presentation with Novadiscovery and Calvagone at the PAGE Meeting
ENYO Pharma is pleased to collaborate with Novadiscovery and Calvagone which will present the first in silico liver disease model and the pharmackinetics-pharmacodynamics analysis respectivelly of EYP001 treatment effect on Hepatitis B virus (HBV) infected patients at the PAGE Meeting, May 29th – June 1st, 2018 in Switzerland.
MIMESIS Newsletter #3: A novel systems biology approach to develop preclinical assets
MIMESIS NEWSLETTER #3, April 2018
A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.
MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.
USA allowance for the FXR agonist use patent in HBV
ENYO Pharma got the USA allowance for its FXR agonist use patent in hepatitis B virus (HBV). The patent was licensed under exclusive agreement from Inserm. FXR agonists change the composition of the transcriptional complex on the HBV cccDNA resulting in repression of HBV cccDNA expression.
Latest Press Release 